Biocon Limited Q2 FY23 Investor Presentation 2022

Biocon Limited's Q2 FY23 investor presentation from November 2022 outlines the company's strategy and performance as a global biopharmaceutical enterprise. The presentation covers growth prospects, R&D efforts, and expansion plans focused on providing affordable, high-quality medicines to patients and healthcare systems worldwide.